In addition, we also analyzed the response to EGFR-TKIs and compared the progression-free survival outcomes for EGFR-TKI treatment (PFS-TKIs) between NSCLC patients with different EGFR double mutation types. Here, EGFR is linked to non-small cell lung carcinoma.